First Time Loading...

Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460

Watchlist Manager
Sihuan Pharmaceutical Holdings Group Ltd Logo
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
Watchlist
Price: 0.61 HKD -1.61% Market Closed
Updated: May 17, 2024
Section:
 

Relative Value

The Relative Value of one Sihuan Pharmaceutical Holdings Group Ltd stock under the Base Case scenario is 0.31 HKD. Compared to the current market price of 0.61 HKD, Sihuan Pharmaceutical Holdings Group Ltd is Overvalued by 48%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
0.31 HKD
Overvaluation 48%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.8
P/S
P/S
Price to Sales
2.8
vs History
58
vs Industry
42
Median 3Y
3.1
Median 5Y
3
Industry
2.5
Forward
2.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.2
Industry
23.5
Forward
224.7
More Details
26.4
P/OCF
P/OCF
Price to OCF
26.4
vs History
31
vs Industry
18
Median 3Y
20.8
Median 5Y
17.6
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
7.8
Industry
24.3
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
46
vs Industry
57
Median 3Y
1.3
Median 5Y
1.2
Industry
2.1
More Details
1
EV/S
EV/S
Enterprise Value to Sales
1
vs History
53
vs Industry
74
Median 3Y
1.4
Median 5Y
1.1
Industry
2.6
Forward
0.8
More Details
1.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.4
vs History
53
vs Industry
79
Median 3Y
1.8
Median 5Y
1.6
Industry
5.3
More Details
23.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
23.5
vs History
4
vs Industry
16
Median 3Y
6
Median 5Y
4.1
Industry
13.7
Forward
-3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
-4.8
Median 5Y
1
Industry
17.4
Forward
-2.3
More Details
9
EV/OCF
EV/OCF
Enterprise Value to OCF
9
vs History
38
vs Industry
39
Median 3Y
9.4
Median 5Y
7.3
Industry
16.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-4.3
Industry
18.6
More Details
0.3
EV/IC
EV/IC
Enterprise Value to IC
0.3
vs History
65
vs Industry
82
Median 3Y
0.5
Median 5Y
0.4
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Sihuan Pharmaceutical Holdings Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
5.7B HKD 2.8 -97.5 23.5 -12.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
731.8B USD 20.4 119.2 58.5 66.5
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 16.5 45.1 33.6 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.2B USD 4.3 9.7 11.9 15.5
US
Merck & Co Inc
NYSE:MRK
332.3B USD 5.4 144.1 35.8 58.4
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP 5 37.6 174.5 278.3
CH
Roche Holding AG
SIX:ROG
189B CHF 3.2 16.4 9.3 11
CH
Novartis AG
SIX:NOVN
182.7B CHF 3.4 11.5 8.7 12.8
US
Pfizer Inc
NYSE:PFE
161.3B USD 2.9 -522.1 12.9 20.6
P/E Multiple
Earnings Growth
CN
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
Average P/E: 54.8
Negative Multiple: -97.5 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.2
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.7
-20%
US
Merck & Co Inc
NYSE:MRK
144.1
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -522.1
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.